Lobbying client
AMNEAL
Generic drug issues.
Filings
7
Filed by
1
Reported in-house
—
Reported by firms
$340,000
Reported lobbying by year
The larger of in-house and firm-reported each year, $ thousands
2020 to 2022
Filings
7 filings, newest first.
| Filing | Filed by | Amount |
|---|---|---|
|
1st Quarter - Termination 1st Quarter 2022
|
MEHLMAN CONSULTING, INC. | $40,000 reported |
|
4th Quarter - Report 4th Quarter 2021
|
MEHLMAN CONSULTING, INC. | $60,000 reported |
|
3rd Quarter - Report 3rd Quarter 2021
|
MEHLMAN CONSULTING, INC. | $60,000 reported |
|
2nd Quarter - Report 2nd Quarter 2021
|
MEHLMAN CONSULTING, INC. | $60,000 reported |
|
1st Quarter - Report 1st Quarter 2021
|
MEHLMAN CONSULTING, INC. | $60,000 reported |
|
4th Quarter - Report 4th Quarter 2020
|
MEHLMAN CONSULTING, INC. | $60,000 reported |
|
Registration 4th Quarter 2020
|
MEHLMAN CONSULTING, INC. | — reported |
Filed by
Each firm that has reported for this client, and the client itself where it lobbies in-house, with the reports filed and the amounts they disclose.
| Firm | Reports | Amount |
|---|---|---|
| MEHLMAN CONSULTING, INC. | 6 | $340,000 |
Issues lobbied
How many report sections named each issue, counting the current version of each report.
| Issue | Code | Mentions |
|---|---|---|
| Pharmacy | PHA | 7 |
| Manufacturing | MAN | 6 |
| Health Issues | HCR | 1 |
Bills named in its filings
Bill numbers found in the filers' descriptions, most often named first.
| Bill | Congress | Times named |
|---|---|---|
| H.R. 5376 | 117th | 4 |
| S. 1176 | 117th | 4 |
| S.Con.Res. 14 | 117th | 2 |
| S. 3799 | 117th | 1 |
From reports filed under the Lobbying Disclosure Act. Firms report what each client paid them; an organisation lobbying for itself reports its own expenses. Amounts count the current version of each report once.